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Abstract
Background: Despite the high prevalence of subthreshold depression in patients with type 2 diabetes, evidence
on cost-effectiveness of different therapy options for these patients is currently lacking.
Methods/Design: Within-trial economic evaluation of the diabetes-specific cognitive behaviour therapy for
subthreshold depression. Patients with diabetes and subthreshold depression are randomly assigned to either 2
weeks of diabetes-specific cognitive behaviour group therapy (n = 104) or to standard diabetes education
programme only (n = 104). Patients are followed for 12 months. During this period data on total health sector
costs, patient costs and societal productivity costs are collected in addition to clinical data. Health related quality of
life (the SF-36 and the EQ-5D) is measured at baseline, immediately after the intervention, at 6 and at 12 months
after the intervention. Quality adjusted life years (QALYs), and cumulative costs will be estimated for each arm of
the trial. Cost-effectiveness of the diabetes-specific cognitive behaviour group therapy will be analysed from the
perspective of the German statutory health insurance and from the societal perspective. To this end, incremental
cost-effectiveness ratio (ICER) in terms of cost per QALY gained will be calculated.
Discussion: Some methodological issues of the described economic evaluation are discussed.
Trial registration: The trial has been registered at the Clinical Trials Register (NCT01009138).
Background
Depression is a highly prevalent disorder with a substan-
tial impact on quality of life and societal cost [1,2]. This
applies in particular to patients with diabetes, since
depression has been shown to be more prevalent among
these patients as compared to those without diabetes
[3-5]. Previous research demonstrates that comorbid
depression in patients with diabetes is associated with
poor self care, i.e. adherence to medication, diet, exer-
cise and smoking cessation [6-8], additive functional
impairment and work disability [9], poorer glycaemic
control [10], higher risk of microvascular and
macrovascular complications [11,12], decreased quality
of life [13], and higher mortality [14,15] as compared to
patients with diabetes only. Many studies also found
higher overall health care cost in depressed patients, not
explained by higher mental health treatment costs alone.
This association persisted even after adjustment for
comorbid medical conditions [see e.g. [7,16-19]]. A US
study [17] found 4.5-times higher total annual health-
care costs for Medicare patients with diabetes and
comorbid depression than for diabetic patients without
depression ($247,000,000 and $55,000,000, respectively;
P < 0.0001 (cost adjusted to reflect August 2001 dollars).
Hence, the more effective depression treatment might
not only improve health outcomes, but also reduce total
health service utilization and therefore costs. Put differ-
ently, additional costs for improved depression
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care costs. In the IMPACT trial [20] for example, sys-
tematic depression treatment in older adults with
diabetes had significant clinical benefit with no increase
in overall healthcare costs. The Pathways Study [21] also
found that over a 2-year period the increased costs asso-
ciated with enhanced mental health treatment were off-
set by savings in total medical expenditures.
Cost-effectiveness of treatment options for depression
has been mainly evaluated for major depression co-
occurring with diabetes. However, there is a need to
examine the cost-effectiveness of therapies for subthres-
hold depression as well, since there is evidence that
about 20% of patients with diabetes have elevated
depressive symptoms without meeting criteria for major
clinical depression [4,5]. In what follows, a within-trial
economic evaluation of a diabetes-specific cognitive
behaviour therapy in patients with type 2 diabetes and
subthreshold depression is outlined.
Methods/Design
Clinical trial
The clinical trial is carried out as randomised clinical
trial comparing a diabetes-specific cognitive behaviour
group therapy (DS-CBT) to a standard diabetes educa-
tion programme (DEP). The trial is carried out in the in
the Diabetes Centre Mergentheim, Germany, where
about 6500 diabetic patients are treated annually.
Approval for the study was granted by the local Medical
Ethics Committee (Ethikkommission der Ärztekammer
des Landes Baden-Württemberg). Primary endpoint of
the clinical trial is the reduction of subthreshold depres-
sion at the 12 months follow up. Secondary variables
are improvement of glycaemic control (HbA1c), health
related quality of life (SF-36 and EQ-5D), diabetes
related distress, and diabetes self-management. Assess-
ments take place before the intervention (baseline), after
the core intervention (at 2 weeks), and at 6 and 12
months of the trial.
Sample size calculation
A remission in 65% and 40% of cases is assumed under
the DS-CBT and DEP respectively. To detect a statisti-
cally significant difference with a power (1-b) of 90% (2-
sided t-test, a = 0.05) 83 patients in each treatment
group are required. Assuming a loss to follow-up of
20%, 104 patients in each arm of the trial are needed.
Study sample
Patients with type 2 diabetes and elevated depressive
symptoms (ADS > 22) [22], but without clinical depres-
sion according to Composite International Diagnostic
Interview [23], 18 to 70 years of age who gave informed
consent are included into the trial. Exclusion criteria
comprise treatment with anti-depressant drugs, diagno-
sis of acute psychiatric illness and severe somatic illness.
Interventions
Trials participants are randomly assigned either to the
intervention group that receives the DS-CBT in addition
to the standard diabetes education programme or to a
control group that receives only standard diabetes edu-
cation programme offered by the Diabetes Centre Mer-
gentheim. The DS-CBT consists of 10 lessons of 45
minutes each, delivered in 5 sessions of 90 minutes in a
group setting within a period of 2 weeks. Each DS-CBT
group consists of minimum 3 and maximum 8 mem-
bers. The DS-CBT is based on an evaluated German
manual of cognitive behaviour therapy [24], which has
been modified according to diabetes-specific topics (cop-
ing with self monitoring, self injecting of insulin, reac-
tions of others to diabetes, coping with late
complications, hypoglycaemia problems, keeping a
healthy diet, barriers to lifestyle modification). Further-
more, 4 telephone contacts within the following year are
offered as booster sessions in addition to the 5 sessions
of the “core intervention”. The diabetes education pro-
gramme includes continuous education and group ses-
sions to optimise the diabetes management as well as
workshops and lessons with diabetes-specific topics.
Within-trial economic evaluation
The objective of the economic evaluation, which is con-
ducted alongside the trial, is to estimate the cost-effec-
tiveness of the DS-CBT in terms of costs per quality
adjusted year (QALY) from the perspective of the Ger-
man statutory health insurance and from the societal
perspective. To this end an incremental cost-effective-
ness ratio (ICER) will be calculated, i.e. the ratio of the
difference in costs between DS-CBT and DEP groups
divided by the difference in QALYs gained in each
group. Under statutory health insurance perspective on
cost, ICER will be calculated using health sector costs
only. Adopting the societal perspective, also patient
costs and societal productivity costs will be added to the
calculation of the ICER.
Estimating effects of intervention in terms of QALYs
For the purposes of economic analysis, measures com-
parable across various interventions as well as across
different disease areas are preferred. Most popular out-
come measure for this purpose are the quality adjusted
life-years (QALYs), which explicitly combine length and
quality of life in a single measure, weighting survival (a
set of health states) by utility scores. Utility weights
reflect preferences for a particular health state and are
m e a s u r e do nas c a l ef r o m0t o1 ,w h e r e0a n d1r e p r e -
sent death and full health, respectively [25]. Although
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of its protocol, it does include the SF-36 and the EQ-5D
questionnaires measuring health related quality of life.
Standardized algorithms exist to translate EQ-5D and
SF-36 scores into utility weights suitable for calculation
of QALYs [26-28].
More than 15 value sets are available for scoring the
EQ-5D, based on rating scale and time trade-off (TTO)
valuation derived from general population surveys in
various countries (including the United Kingdom, Ger-
many, and the United States) [28]. In this study the
scoring function derived from a survey of the general
population in Germany will be used to calculate utility
weights from EQ-5D responses [29].
Brazier and colleagues reported work on deriving a
reduced health status index from the SF-36 that they
termed the SF-6D [30] and more recently, they have
published an algorithm that allows the estimation of uti-
lity weights for all states of the SF-6D index [31]. Fol-
lowing this published algorithm, SF-36 scores observed
in the trial will be converted to utility weights. Since the
values underlying this algorithm were obtained in the
United Kingdom, utilities derived from SF-36 scores will
be only used to perform a sensitivity analysis.
The SF-36 and EQ-5D will be administered at base-
line, immediately after the intervention, at 6 months and
at 12 months after the intervention (see Table 1).
Hence, a maximum of four possible observations for SF-
36 and EQ-5D scores and derived utility weights will be
available for each patient enrolled in the trial. QALYs
will be calculated assuming linear interpolation between
measurement points and calcul a t i n gt h ea r e au n d e rt h e
curve to give a number of QALY gained per patient
over the trial period [25].
Measurement of resource use
Resource use and costs directly associated with DS-CBT
and DEP (e.g. staff time) will be derived from the ther-
apy protocols. Information on the utilisation of other
healthcare services will be obtained from trial partici-
pants by means of a cost questionnaire, which was
developed for the study and incorporated into the case
report files of the trial. The questionnaire is adminis-
tered before the intervention (baseline), at 6, and 12
months of the trial and refers to the previous 6 months
(see Table 1). The cost form includes structured no/yes
questions on the utilisation of different medical services
under the following categories: primary care visits, visits
to emergency departments, visits to specialists, hospital
stays, medication, and other therapies/paramedical care.
If patients indicate that they received specific medical
care over the past 6 months, they are asked to specify
the volume: e.g. number of contacts with healthcare
providers, number and length of hospitalizations, types
and dosage of obtained medications. In the cost ques-
tionnaire patients are also asked to indicate whether
health care services obtained by them were paid by the
health insurance or self-paid, which makes an assess-
ment of out-of-pocket expenses possible. Furthermore,
the number of “days missed from work” will be regis-
tered with the cost questionnaire.
Estimating costs
Health sector costs
To estimate costs from the statutory health insurance
perspective, healthcare resource use due to interventions
and other reported healthcare utilization (consultations,
hospital days, etc.) will be multiplied by unit costs/
prices. Currently, there aren oG e r m a ng u i d e l i n e sf o r
costing in economic evaluations containing standard
unit costs. Hence, healthcare resource use will be valued
by unit costs/prices obtained from published sources
and official statistics for Germany (e.g. charges and rates
from administrative databases, pharmacy retail prices).
Patient costs
To estimate patient costs, reported consumption of
healthcare services paid out of pocket will be multiplied
by unit costs/prices available from official statistics and
from providers.
Societal productivity costs
Days missed from work will be monetary valued accord-
ing to the human capital approach [25].
Statistical analysis of costs and effects
Mean total costs, health sector costs, patient costs and
p r o d u c t i v i t yc o s t sa sw e l la sc o r r e s p o n d i n gc o s td i f f e r -
ences between the DS-CBT group and DEP group will
be calculated. Sampling uncertainty (95% confidence
intervals) will be estimated using bootstrap procedure
because cost data are non-normally distributed.
Table 1 Endpoints, measurement instruments and time of data collection
Endpoint Questionnaire Time of measurement
Baseline 2 weeks 6 months 12 months
QALYs EQ-5D SF-36 xx x x
Health sector costs Health care utilisation and cost questionnaire xx x
Patient costs Health care utilisation and cost questionnaire xx x
Productivity Costs Health care utilisation and cost questionnaire xx x
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regression on type of intervention and - if necessary -
on baseline utility score, which has been shown to be
important for the unbiased assessment of mean QALY
differences between treatment groups [32].
Imputation of missing information on costs and effects
Data will be analysed according to the intention to treat
principle. A multiple imputation approach based on pro-
pensity scoring will be used to account for missing
information with regard to effects and costs. Baseline
variables (e.g. age, gender, cost at baseline, etc.) will be
entered into a logistic regression to predict the chance
of a missing value [33,34]. Available data will be
arranged into quintiles based on this predicted probabil-
ity (propensity score) and a replacement value for miss-
ing data will be selected at random from the available
data points within the same quintile. By choosing a
value at random within the same quintile the principle
of multiple imputations could be employed, whereby
each missing value is replaced by m > 1 simulated
values [35-37]. Each of m resulting data sets will be ana-
lysed as described above and combined to produce a
single result that takes uncertainty in the imputation
process into account.
Determining cost-effectiveness
If a significant impact of DS CBT on both effects and
costs is demonstrated, ICER will be estimated in terms
of costs per QALY gained. ICER will be estimated for
the total cost (health sector costs plus patient costs plus
societal productivity costs) and for the health sector
costs only (statutory health insurance perspective). The
non-parametric bootstrap method will be employed to
generate confidence intervals around the ICER estimates
derived from the study sample [38,39]. Uncertainty sur-
rounding the ICER will also be presented on the cost-
effectiveness plane [40,41] and as the cost-effectiveness
acceptability curve [42,43].
Sensitivity analyses
Besides statistical uncertainty (sampling variation) with
regard to costs and effects, every economic evaluation
may contain some degree of data imprecision (e.g.
resource costs/prices) and methodological controversy
(e.g. derivation of utility weights, discount rate), which
should be accounted for. To handle this type of
uncertainty, sensitivity analysis is usually employed
[25,44]. In the sensitivity analysis (uncertain) parameter
(s) of the base-case analysis are varied to determine if
changes in these parameters influence the results. Uni-
variate sensitivity analyses will be performed by varying
health service unit costs and utility weights (see Table
2). To appreciate the potential influence of missing
responses and of the imputation method chosen, com-
plete case analysis will be performed. We will report
both the revised point estimates and revised confidence
intervals for costs, effectiveness, and cost-effectiveness
that result from the sensitivity analyses.
Discussion
In the context of the trial, it might be argued that, if
true randomisation is achieved, any differences in cost
between treatment arms can be attributed to the study
intervention [45]. Hence, data on utilisation of a broad
range of health services will be collected in the trial.
This approach allows measuring any changes in
resource use related to the interventions being com-
pared. On the other hand, however, it may complicate
the detection of statistically significant difference in
health service costs, since the latter have been shown to
be highly variable and therefore to require larger overall
sample sizes [45,46].
Information on healthcare utilisation other than DS-
CBT and DEP sessions will be collected by self-report
by means of the cost questionnaire. To our knowledge
no standard and validated instruments for collecting
resource use data in clinical trials are available in Ger-
many. Hence, we developed a data collection instrument
specifically for this trial. The questionnaire was pilot
tested, but has not yet been validated against other data
sources. Recall bias may potentially occur, since
resource use will be measured over the previous 6
months. However, there is no conclusive evidence
regarding whether a prospective (a cost diary) or a ret-
rospective (a questionnaire) instrument should be better
applied and regarding an appropriate recall interval [45].
Van den Brink et al. found that for the assessment of
healthcare utilization in economic evaluations alongside
clinical trials, a cost questionnaire may replace a cost
diary for recall periods up to 6 months [47] and that
such patients’ self-reports are a valid source of data on
days of hospitalization and out-patient visits, whereas
costs of medication may be underestimated [48].
Table 2 Summary of planed sensitivity analyses
Parameter/methodological assumption Base-case Sensitivity analysis
Utility weights for QALYs derived from the EQ-5D derived from the SF-36
Unit costs/prices of resource use data from published sources and official statistics for Germany varied within a plausible range
Missing data multiple imputation complete case analysis
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Depression and depression symptoms co-occurring with
type 2 diabetes are highly prevalent and associated with
a wide range of adverse outcomes, including less effec-
tive self-care, more severe physical symptoms, greater
functional impairment and disability as well as increased
healthcare utilization and expenditure. However, there is
a lack of evidence on cost-effectiveness of treatment
options for subthreshold depression co-occurring with
diabetes. The described trial-based economic evaluation
will provide additional evidence on cost-effectiveness of
the DS-CBT in this target group.
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